MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
Seres Therapeutics Revenue 2011-2026 | MCRB
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Seres Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126 M | 7.13 M | 145 M | 33.2 M | 34.5 M | 28.3 M | 32.1 M | 21.8 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 145 M | 7.13 M | 53.5 M |
Quarterly Revenue Seres Therapeutics
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 358 K | - | 351 K | - | - | - | - | - | - | - | 310 K | 126 M | -522 K | - | 3.44 M | 1.22 M | 1.49 M | - | 127 M | 5.26 M | 5.72 M | - | 1.42 M | 6.04 M | 8.19 M | - | 7.03 M | 12.5 M | 7.32 M | - | 9.06 M | 4.61 M | 3.97 M | 3.06 M | 23 M | 3.01 M | 3.02 M | 3.04 M | 13 M | 3 M | 2.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 127 M | -522 K | 13.7 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
257 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Happiness Biotech Group Limited
HAPP
|
71.5 K | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
130 K | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
70.9 M | - | 2.54 % | $ 160 B |  France |
 |
AstraZeneca PLC
AZN
|
58.7 B | - | - | $ 96.9 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
Esperion Therapeutics
ESPR
|
403 M | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
80 M | $ 34.45 | 4.74 % | $ 927 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M | Britain |
 |
Forte Biosciences
FBRX
|
18 M | $ 20.31 | 1.2 % | $ 263 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
Grifols, S.A.
GRFS
|
7.21 B | $ 8.19 | 4.46 % | $ 5.57 B |  Spain |
 |
Celyad Oncology SA
CYAD
|
5 K | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
78.6 M | - | -7.31 % | $ 87 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
82 M | $ 6.82 | 1.94 % | $ 187 M |  Israel |
 |
Generation Bio Co.
GBIO
|
19.9 M | - | - | $ 344 M | USA |
 |
IMV
IMV
|
188 K | - | - | $ 13.1 M | Canada |
 |
BioNTech SE
BNTX
|
482 M | $ 90.36 | 2.93 % | $ 21.8 B | Germany |
 |
Autolus Therapeutics plc
AUTL
|
75.4 M | $ 1.62 | -0.61 % | $ 431 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
43 K | - | -4.36 % | $ 27 M | USA |
 |
Compugen Ltd.
CGEN
|
72.8 M | $ 2.71 | -0.92 % | $ 253 M | Israel |
 |
Anika Therapeutics
ANIK
|
113 M | $ 15.14 | 2.16 % | $ 217 M | USA |
 |
Advaxis
ADXS
|
13 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
7.5 M | - | 5.93 % | $ 314 M | Canada |
 |
Incyte Corporation
INCY
|
5.14 B | $ 97.08 | 1.55 % | $ 19 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
48.9 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 3.39 | 4.17 % | $ 5.58 M | Israel |
 |
AIkido Pharma
AIKI
|
123 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |
 |
Coherus BioSciences
CHRS
|
42.2 M | $ 1.51 | 2.03 % | $ 177 M | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
376 M | $ 20.47 | 4.97 % | $ 2.6 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
469 K | - | -11.43 % | $ 502 K | USA |